Merck and Schering-Plough announce a drug development plan that could work to the detriment of Pfizer. Mike Huckman, CNBC pharmaceuticals reporter, has the story.
Topics:
Biotechnology | Pharmaceuticals | Stock Market
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT